EVROSTON LP, ChatzigianniMexi 5, 115 28, Athens, Greece.
Department of Critical Care of Evangelismos Hospital, Medical School of National and Kapodistrian University of Athens, Athens, Greece.
Appl Health Econ Health Policy. 2019 Feb;17(1):111-121. doi: 10.1007/s40258-018-0431-5.
Chronic obstructive pulmonary disease (COPD) is a leading cause of disability and death worldwide, imposing a substantial socioeconomic burden on societies and patients due to the long-term management required.
To assess the economic burden of COPD in Greece and its potential determinants.
A population-based, random-digit dialled, telephone nationwide survey was conducted to recruit patients with COPD in Greece (N = 351). A structured questionnaire was used to collect data. The total annual cost per patient from a societal perspective was calculated.
The mean (95% CI) annual total cost per patient for the management of COPD from a societal perspective was €2150 (€1879-€2443). The total annual cost was mainly driven by the medication cost (36.1%), followed by the cost of hospitalizations (26.7%) and long-term oxygen therapy (13.8%). Multiple generalized linear model revealed that age, COPD Assessment Test (CAT) score and exacerbations were independently associated with the total annual cost.
Investment in interventions aiming at delaying progression of disease, preventing acute exacerbations, and managing chronic symptoms are required to reduce the overall economic burden of COPD in Greece.
慢性阻塞性肺疾病（COPD）是全球范围内导致残疾和死亡的主要原因，由于需要长期管理，给社会和患者带来了巨大的社会经济负担。
评估 COPD 在希腊的经济负担及其潜在决定因素。
采用基于人群的、随机数字拨号的、全国范围的电话调查，在希腊招募 COPD 患者（N=351）。使用结构化问卷收集数据。从社会角度计算每位患者的年度总费用。
从社会角度来看，每位 COPD 患者管理的年度总费用的平均值（95%CI）为 2150 欧元（1879-2443 欧元）。年度总费用主要由药物费用（36.1%）驱动，其次是住院费用（26.7%）和长期氧疗费用（13.8%）。多元广义线性模型显示，年龄、COPD 评估测试（CAT）评分和加重与总年度费用独立相关。
需要投资于旨在延缓疾病进展、预防急性加重和管理慢性症状的干预措施，以减轻希腊 COPD 的总体经济负担。
